Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
May 9, 2017 SAN DIEGO, May 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the first quarter ended March 31, 2017....
May 2, 2017 SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2017 financial results after the market closes on Tuesday, May 9, 2017. The press release wil...
Mar 29, 2017 SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that in connection with its previously disclosed underwritten public offering, the underwriters have ex...
Mar 22, 2017 SAN DIEGO, March 22, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the pricing of an underwritten public offering of 8,750,000 newly issued shares of its ...
Mar 21, 2017 SAN DIEGO, March 21, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. In addition, V...
Mar 7, 2017 SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2016. ...
Feb 27, 2017 SAN DIEGO, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2016 financial results after the market closes on Tuesday, March 7, 2017 f...
Jan 9, 2017 SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provided a corporate update. As of yesterday, 38 subjects have been enrolled at site...
Nov 3, 2016 SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the third quarter ended September 30, 2016....
Oct 25, 2016 SAN DIEGO, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its third quarter 2016 financial results after the market closes on Thursday, November 3, 2016 followed by ...
Page:
1
... NextLast
= add release to Briefcase